Table of Contents
PPT Slide
Safe Harbor
ArQule Profile
ArQule’s Portfolio
The ArQule Advantage
Oncology Opportunity
The Goal of Activated Checkpoint TherapySM (ACTSM ):
The normal cell cycle:
The cancer cell cycle:
ACTSM aims to restore proof-reading to cancer cells:
ACTSM - More Selective than Chemotherapy
E2F Mechanism Summary
ARQ 501: Broad Spectrum & High Potency
ARQ 501: Demonstrated Efficacy in Animal Models of Human Cancer
ARQ 501: Safety Margin in animal models
ArQule’s Lead Anti-Cancer Compound ARQ 501
Clinical Development:ARQ 501 Phase 1 Trial
Centers of Excellence/Investigators
ACTSM Platform: Multiple Drug Targets
p38 MAP Kinase Inhibitors Program for Rheumatoid Arthritis (RA)
p38 MAP Kinase ProgramValidates ArQule Drug Discovery Approach
Early Animal Data: Effects of p38 Compound in RA Model - Ankle Diameter Reduction
Histopathology: Normal Ankle Joint
Vehicle-Treated Ankle Joint - Arthritic Rat
Ankle Joint of Arthritic Rat treated with ArQule p38 MAP Kinase compound (30mg/kg BID)
PPT Slide
ArQule Financials
Milestones 2003
ArQule Profile
|